Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

69 results about "Transferrin receptor binding" patented technology

Interacting selectively and non-covalently with the transferrin receptor. [PMID:9819414, PMID:pm]

Methods of engineering transferrin receptor binding polypeptides

Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
Owner:DENALI THERAPEUTICS INC

Human transferrin receptor binding peptide-drug conjugate

The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and / or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.
Owner:TAKEDA PHARMA CO LTD

Conjugates comprising transferrin receptor binding protein

Provided herein are compounds and conjugates comprising transferrin receptor binding protein, pharmaceutical compositions comprising such conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease) using such conjugates.
Owner:ELI LILLY & CO

Improved transferrin receptor binding proteins

Transferrin receptor binding polypeptides, and their use, are provided that have an amino acid sequence at least 50%, identical to the amino acid sequence of SEQ ID NO: 1, wherein (a) the polypeptide is identical to SEQ ID NO: 1 at residues corresponding to residues 20, 23. 24, 27, 28, 31, 32, 34, 35. 36, 37, 74, 77, 78, 81, 82. 84, 85, and 88 in SEQ ID NO: 1; and (b) the polypeptide is substituted relative to SEQ ID NO: I as shown in Table 1 at least at 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34. 35, or more residues relative to SEQ ID NO: 1.
Owner:UNIV OF WASHINGTON

Transferrin receptor binding proteins and uses thereof

PCT designated stage expiredWO2025085352A1Nervous disorderAntibody ingredientsCns diseaseCell biology
Provided herein are proteins comprising TfR binding protein, conjugates comprising such TfR binding proteins, e.g., TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease) using TfR binding proteins or conjugates. Also included are methods of treating or reducing pain.
Owner:ELI LILLY & CO

Transferrin receptor binding proteins and conjugates

Provided herein are proteins comprising one monovalent human TfR binding domain ("human TfR binding proteins"), conjugates comprising such human TfR binding proteins, e.g., human TfR binding proteins-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of treating CNS diseases (e.g., neurodegenerative disease such as neurodegenerative synucleinopathy or tauopathy) using human TfR binding proteins or conjugates.
Owner:ELI LILLY & CO

Receptor-mediated endocytosis for targeted internalization and degradation of g protein-coupled receptors

Disclosed are fusion proteins (homodimers and heterodimers thereof). Fusion proteins that can bind to a protein of interest that is a G Protein-Coupled Receptor (GPCR) and to an internalizing receptor on a cell surface (transferrin receptor). Once bound, the protein of interest can be internalized and / or degraded inside a cell.
Owner:DANA FARBER CANCER INSTITUTE INC

Compositions and methods for selective depletion of target molecules

Described herein are compositions and methods for selective depletion of target molecules using a recyclable CDP-receptor-binding mediated complex to elicit endocytosis and cellular degradation of the target. Exemplary compositions containing a peptide, such as a CDP peptide, that bind a transferrin receptor can be linked to a peptide that binds a target molecule. Such compositions can be used to selectively recruit the target molecule to endosomes via transferrin receptor-mediated endocytosis of the composition and the bound target molecule. Once inside the endosome, the acidic pH can lead to release of the target molecule from the composition due to pH-dependent binding of the composition for the target molecule, and the transferrin receptor portion is recycled back to the cell surface for “reloading”. The target molecule can then be trafficked into lysosomes wherein it is degraded.
Owner:FRED HUTCHINSON CANCER CENT +1

Bispecific antibodies that bind to protease-like domain of human transferrin receptor htfr1

PendingCN121079325ANervous disorderAntibody ingredientsImmunoglobulin Heavy Chain Variable RegionEpitope
The present disclosure relates to binding proteins comprising: a first transferrin receptor 1 binding moiety M1 comprising an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL) and having the ability to selectively bind to an epitope located in the hTfR1 protease-like domain; and a second portion M2, the M2 comprising an antibody Fc domain. In the binding protein, M1 and M2 are linked to each other by at least one peptide linker between M1 and M2.
Owner:BIOARCTIC AB

Transferrin receptor binding molecules, their conjugates, and their use for the prevention or treatment of neurological disorders.

The present invention relates to variable domains (VHHs) of camelid heavy chain molecules that bind to TfR, conjugate compounds containing such VHH molecules, and their use for, for example, transporting molecules for pharmaceutical purposes to cells and organs in pathological conditions in the CNS or PNS, including cancer.
Owner:VECTOR-ALL +2

Transferrin receptor-binding molecules, conjugates thereof and their uses

The invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules which bind TfR and the uses thereof e.g., to transport molecules of pharmaceutical or diagnostic interest into cells and in organs, in pathological conditions including cancer.
Owner:VECT HORUS +2

Anti-transferrin receptor (TfR) antibody and uses thereof

Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of making and using the antibodies are also provided.
Owner:DYNE THERAPEUTICS INC

A beta targeting proteins and methods of use

Described herein are A [beta]-targeting proteins comprising an A [beta]-binding region; a transferrin receptor (TfR) binding region that specifically binds to the TfR with an affinity of from about 900 nM to about 10,000 nM; and an Fc [gamma] R binding region. Also described are methods of making the A [beta]-targeting proteins and methods of using the A [beta]-targeting proteins in the treatment of neurodegenerative disorders.
Owner:DENALI THERAPEUTICS INC

Fe-based T7 peptide targeted glioma micromolecular magnetic resonance contrast agent and preparation and synthesis method and application thereof

The invention discloses a Fe-based T7 peptide targeted glioma micromolecular magnetic resonance contrast agent and a synthesis method and application thereof.The micromolecular magnetic resonance contrast agent is characterized in that one part of the micromolecular magnetic resonance contrast agent is targeted peptide, the other part of the micromolecular magnetic resonance contrast agent is an iron-coordinated pyridine ring contrast agent, and the targeted peptide and the iron-coordinated pyridine ring contrast agent are connected through click reaction. The T7 peptide part in the micromolecule magnetic resonance contrast agent can be combined with a transferrin receptor and can be more efficiently conveyed to the brain for imaging. Compared with a traditional Gd-based contrast agent, the magnetic resonance contrast agent disclosed by the invention has higher specificity and lower toxicity, and meanwhile, the contrast agent has better stability and can be used for efficiently imaging in-situ brain glioma.
Owner:INNOVATION ACAD FOR PRECISION MEASUREMENT SCI & TECH CAS

Human transferrin receptor binding peptide

Novel peptides that bind to the human transferrin receptor (hTfR) are provided. The peptide is a peptide comprising an amino acid sequence described in Ala-Val-MePhe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-K(MePEG4c)-Arg-Phe-MeTyr-Cys (SEQ ID NO: 1), or the peptide comprising one or more predetermined substitutions in the amino acid sequence described in SEQ ID NO:1.
Owner:PEPTIDREAM INC +1

Transferrin receptor binding domains and proteins comprising same

Provided herein are transferrin receptor binding domains, polypeptides comprising transferrin receptor binding domains, and antibodies and antibody fragments comprising transferrin receptor binding domains, and uses thereof.
Owner:DENALI THERAPEUTICS INC

Cell-targeting complexes and uses thereof

Provided are transferrin receptor binding VHH domains as well as delivery complexes and methods for targeting cells of interest for delivery of an active cargo such as an oligomeric agent. In particular, the delivery complex may comprise modified Fc domain and a transferrin receptor binding VHH domain.
Owner:IONIS PHARMACEUTICALS INC

Ferritin variants with increased stability, complexing ability and transferrin receptor affinity

ActiveCN115515966BAspartic acid residueDisease
The present invention relates to a polypeptide comprising a transferrin receptor binding domain (TRBD) of a ferritin variant. The TRBD comprises one or more than one glutamine residue mutated to a glutamic acid residue and / or one or more than one asparagine residue mutated to an aspartic acid residue. The present invention also relates to a complex of the polypeptide and a tag or a drug, and an isolated cell delivery system comprising the polypeptide or the complex of the present invention, and the use of the system for prevention, treatment, diagnosis or diagnosis-treatment, in particular for treating cancer or an inflammatory disease.
Owner:CELLIS AG

Glycosyl functional nucleic acid-based cross-blood-brain-barrier nucleic acid drug delivery system as well as preparation method and application thereof

The invention discloses a blood-brain barrier crossing nucleic acid drug delivery system based on glycosyl functional nucleic acid and a preparation method and application thereof, and belongs to the technical field of biomedicine. The core of the system is a glycosylated transferrin receptor aptamer (GTA), and the GTA is formed by covalently linking a glycosyl modification module and a transferrin receptor binding sequence and can be combined with therapeutic nucleic acid to form a compound. According to the invention, the blood-brain barrier crossing efficiency and brain targeting property of nucleic acid drugs are remarkably improved through a dual-channel synergistic mechanism formed by transferrin receptor mediated transfection and glucose transporter assisted uptake; the GTA can be automatically prepared through a DNA solid-phase synthesis platform, and is controllable in structure, stable in batch, high in biocompatibility and low in immunogenicity. The delivery system can be compatible with multiple nucleic acid drugs such as siRNA, ASO and CpG ODN, and has a wide application prospect in treatment of central nervous system diseases such as glioblastoma.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Transferrin receptor binding proteins and conjugates

Provided herein are proteins comprising a monovalent human TfR binding domain ("human TfR binding proteins"), conjugates comprising such human TfR binding proteins, e.g., human TfR binding protein-dsRNA conjugates, pharmaceutical compositions comprising human TfR binding proteins or conjugates, and methods of using human TfR binding proteins or conjugates to treat CNS diseases, e.g., neurodegenerative diseases such as neurodegenerative synucleinopathies or tauopathies.
Owner:ELI LILLY & CO

Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat nervous system diseases

PCT designated stage expiredWO2024261333A1Nervous disorderAntibody mimetics/scaffoldsHeavy chainCamelid
The invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules which bind TfR, the conjugate compounds comprising such VHH molecules, and the uses thereof e.g., to transport molecules of pharmaceutical interest into cells and in organs, in pathological conditions of the CNS or PNS, including cancer.
Owner:VECT HORUS +2

Compounds for the delivery of granulin across the blood brain barrier

PCT designated stage expiredWO2024263567A9Nervous disorderAntibody ingredientsAlbuminPharmacology
Compounds for the delivery of progranulin, a progranulin fragment, and / or at least one granulin protein subunit across the blood brain barrier. Compounds for the delivery of progranulin, a progranulin fragment, and / or at least one granulin protein subunit across the blood brain barrier, the compounds including a progranulin domain, a TfR1 binding domain, and optionally an albumin binding domain. Compounds for the delivery of wildtype or unmodified progranulin across the blood brain barrier.
Owner:ELI LILLY & CO

TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers

The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain. The present invention relates to a transcytosis selection method to obtain VNARs against mammalian blood brain barrier (BBB) receptors using phage display libraries as well as against receptors found in other directional cell barrier systems like the gastrointestinal tract and other organs. The VNARs may be used alone or as components in compositions or as conjugates that target the particular receptor transport systems for delivery of therapeutics or diagnostics to the brain (in the case of BBB receptors) or other tissues.
Owner:OSSIANIX INC

Engineered transferrin receptor binding peptides as well as methods of making and using the same

Engineered transferrin receptor (TfR) binding peptides are disclosed that can be used to deliver a therapeutic agent into a cell, tissue, organ or system of an individual. Conjugates, fusions, delivery vehicles and pharmaceutical compositions including the same also are disclosed, as well as methods of using the same for treating central nervous system (CNS) diseases, disorders or conditions or for treating TfR-associated diseases, disorders or conditions.
Owner:ELI LILLY & CO

Transferrin receptor (TFR) aptamers and use thereof

The invention relates to compounds comprising advantageous novel aptamers and aptamer conjugates, as well as compositions comprising the same, and their use in therapy or diagnosis. In particular, disclosed herein are aptamers and aptamer conjugates that bind to the human transferrin receptor (1) (hTfRl) without competing with human transfenin (hTf) for binding to hTfRl.
Owner:CREYON BIO INC